Announcements
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
- Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
- Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
- Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
- Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
More ▼
Key statistics
On Friday, Xenon Pharmaceuticals Inc (XP0:FRA) closed at 37.60, -19.31% below its 52-week high of 46.60, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.60 |
---|---|
High | 37.60 |
Low | 37.60 |
Bid | -- |
Offer | -- |
Previous close | 39.00 |
Average volume | 42.40 |
---|---|
Shares outstanding | 75.43m |
Free float | 74.05m |
P/E (TTM) | -- |
Market cap | 3.04bn USD |
EPS (TTM) | -2.73 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 07:03 BST.
More ▼